Tom Harkin: “I thank my friend from New Jersey for the opportunity to clarify this point. The Senator is correct that this provision…”

“I thank my friend from New Jersey for the opportunity to clarify this point. The Senator is correct that this provision aims to provide incentives in the form of extended market exclusivity for certain antibacterial and antifungal drugs that treat serious or life- threatening infections. He is also correct that the list of qualified pathogens in the legislation is illustrative, and not exhaustive. Products intended to treat serious or life threatening infections caused by gram negative anaerobic bacteria would be qualified infectious disease products and would therefore be eligible for the 5 years of extended market exclusivity.”